18
Feb

Cambridge, MA’s Akebia Therapeutics is lining up for a $75 million Wall Street debut, looking to raise cash and get its promising anemia drug into late-stage development.

…read more

Source: Akebia swings for a $75M IPO to get its anemia drug into Phase III

    

0 No comments